Author

Daniela Pugliese

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

Daniela Pugliese  et al.

HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS
HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS

Daniela Pugliese  et al.

IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Daniela Pugliese  et al.

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Daniela Pugliese  et al.

ENDOSCOPIC BALLOON DILATATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN’S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE
ENDOSCOPIC BALLOON DILATATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN’S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE

Daniela Pugliese  et al.

RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE

Daniela Pugliese  et al.

TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY
TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY

Daniela Pugliese  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Daniela Pugliese  et al.

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Daniela Pugliese  et al.

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

Daniela Pugliese  et al.

THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY
THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY

Daniela Pugliese  et al.

INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD
INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD

Daniela Pugliese  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Daniela Pugliese  et al.

REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Daniela Pugliese  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

Daniela Pugliese  et al.

ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS
ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS

Daniela Pugliese  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Daniela Pugliese  et al.

Item 1 - 18 / 18
1